Ratifi Español Sign in
Ratifi

Federal bills from Congress.gov. State bills from Open States.

A 3328Session 222

Prohibits sale of certain products using advertisements alluding to controlled dangerous substances or analogs.

Introduced

ASSEMBLY, No. 3328

STATE OF NEW JERSEY

222nd LEGISLATURE

PRE-FILED FOR INTRODUCTION IN THE 2026 SESSION


Sponsored by:

Assemblyman STERLEY S. STANLEY

District 18 (Middlesex)

SYNOPSIS

     Prohibits sale of certain products using advertisements alluding to controlled dangerous substances or analogs.

CURRENT VERSION OF TEXT

     Introduced Pending Technical Review by Legislative Counsel.


An Act concerning the sale of products using certain advertisements and supplementing P.L.1960, c.39 (C.56:8-1 et seq.).

     Be It Enacted by the Senate and General Assembly of the State of New Jersey:

     1.    It shall be an unlawful practice for any person to sell, or offer for sale, any merchandise which uses any advertisement, on its packaging or elsewhere, which directly or indirectly links the product to, or otherwise alludes to, any controlled dangerous substance or analog:

     a.     To a person under 18 years of age; or

     b.    If the product is a food, beverage, or intended to be ingested or inhaled.

     The provisions of this act shall not apply to any prescription medication that is dispensed by a pharmacist pursuant to a valid prescription.

     2.    This act shall take effect on the first day of the third month next following enactment.

STATEMENT

     This bill prohibits the sale of certain items which use advertisements linked or alluding to controlled dangerous substances or analogs.  The bill bans the sale of any food, beverage, or other product meant to be ingested or inhaled which uses the advertisement on its packaging or elsewhere.  The bill further prohibits the sale of any product using the advertising, regardless of the product’s intended use, to a person under 18 years of age.  The bill specifies that the provisions do not apply to any prescription medication dispensed by a pharmacist pursuant to a valid prescription.

     A violation under the bill would be an unlawful practice under the consumer fraud act, which is punishable by a monetary penalty of not more than $10,000 for a first offense and not more than $20,000 for any subsequent offense.  Additionally, a violation can result in a cease and desist order issued by the Attorney General, the assessment of punitive damages, and the awarding of treble damages and costs to the injured.

Official text from the New Jersey Legislature. Formatting has been adapted for reading on Ratifi.